Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/125917COMPARTIR / EXPORTAR:
 SHARE
 CORE
BASE
|
|
| Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
| Campo DC | Valor | Lengua/Idioma |
|---|---|---|
| dc.contributor.author | Montes, Ariana | - |
| dc.contributor.author | Márquez, Ana | - |
| dc.contributor.author | González, Antonio | - |
| dc.date.accessioned | 2015-11-25T17:57:13Z | - |
| dc.date.available | 2015-11-25T17:57:13Z | - |
| dc.date.issued | 2015-03-18 | - |
| dc.identifier.citation | Arthritis Research & Therapy 17(1): 63 (2015) | - |
| dc.identifier.issn | 1478-6354 | - |
| dc.identifier.uri | http://hdl.handle.net/10261/125917 | - |
| dc.description | Montes, Ariana et al. | - |
| dc.description.abstract | [Introduction] We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). | - |
| dc.description.abstract | [Methods] The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (ΔDAS28) and the European League Against Rheumatism (EULAR) response criteria. | - |
| dc.description.abstract | [Results] An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in ΔDAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication. | - |
| dc.description.abstract | [Conclusions] Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA. | - |
| dc.description.sponsorship | Funding was provided by grants PI11/01048, PI12/01909 and by RETICS Program, RD08/0075/0019 and RD12/0009/0008 (RIER) of the Instituto de Salud Carlos III (Spain) that are partially financed by the European Regional Development Fund of the European Union. | - |
| dc.publisher | BioMed Central | - |
| dc.relation.isversionof | Publisher's version | - |
| dc.rights | openAccess | - |
| dc.title | Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study | - |
| dc.type | artículo | - |
| dc.identifier.doi | 10.1186/s13075-015-0571-z | - |
| dc.relation.publisherversion | http://dx.doi.org/10.1186/s13075-015-0571-z | - |
| dc.identifier.e-issn | 1478-6362 | - |
| dc.date.updated | 2015-11-25T17:57:13Z | - |
| dc.language.rfc3066 | en | - |
| dc.rights.holder | Montes et al.; licensee BioMed Central. | - |
| dc.rights.license | http://creativecommons.org/licenses/by/4.0 | - |
| dc.contributor.funder | Instituto de Salud Carlos III | - |
| dc.contributor.funder | European Commission | - |
| dc.relation.csic | Sí | - |
| dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
| dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
| dc.identifier.pmid | 25885039 | - |
| dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.fulltext | With Fulltext | - |
| item.cerifentitytype | Publications | - |
| item.openairetype | artículo | - |
| item.grantfulltext | open | - |
| Aparece en las colecciones: | (IPBLN) Artículos | |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| 13075_2015_Article_571.pdf | 1,68 MB | Adobe PDF |  Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
5
checked on 13-abr-2024
SCOPUSTM
Citations
9
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
10
checked on 28-feb-2024
Page view(s)
301
checked on 18-abr-2024
Download(s)
273
checked on 18-abr-2024
